Scancell and PharmaJet to use Stratis® IM Needle-free delivery System for SCIB1/iSCIB1+ vaccine for Advanced Melanoma
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “Securing long term supply for the PharmaJet Stratis® Intramuscular Needle-free Injection System is an important step in allowing the clinical and commercial development of SCIB1/iSCIB1+. We are pleased that PharmaJet’s delivery system works effectively with our SCIB1/iSCIB1+ therapeutic cancer vaccines and offers a well-received immunisation for patients. Our ultimate goal for Scancell is to deliver an off the shelf, safe, tolerable, effective therapy that can provide potent and durable anti-tumour responses for unresectable stage IV melanoma which currently has a 5-year survival of 35%, according to the SEER database, and we believe this agreement will bring us another step closer to achieving this goal.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the